Clinical trial
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565
Study timeline
Study start (actual)2020-10-28Date precision: day
Registry last updated2026-04-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-negative Breast Cancerunresolved
Triple Negative Breast Cancerunresolved
Interventions
CapecitabineDRUG · verified · RxNorm: capecitabine
CarboplatinDRUG · verified · RxNorm: carboplatin
CisplatinDRUG · verified · RxNorm: cisplatin
Sacituzumab govitecanDRUG · verified · RxNorm: sacituzumab govitecan
Sponsors & collaborators
GBG Forschungs GmbHlead sponsor
Gilead Sciencescollaborator
Austrian Breast & Colorectal Cancer Study Groupcollaborator
Spanish Breast Cancer Research Group (GEICAM)collaborator
ETOP IBCSG Partners Foundationcollaborator
Cancer Trials Irelandcollaborator
UNICANCERcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04595565 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.